This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
Economy · News reference
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?
While Wall Street analysts maintain a bullish average brokerage recommendation (ABR) of 1.56 for Astrazeneca with 17 Strong Buy ratings, the Zacks Rank system assigns the stock a Strong Sell rating (#5). This contradiction stems from a 10.3% decline in consensus earnings estimates over the past month to $9.16, indicating analyst pessimism about the company's earnings prospects. The article cautions investors against relying solely on brokerage recommendations, which often exhibit positive bias, and suggests the Zacks Rank's focus on earnings estimate revisions is a more reliable predictor of near-term stock performance.
AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’
CNBC traders picked AstraZeneca, Leidos, 10-year Treasuries and Expeditors; strong earnings lifted Leidos and Expeditors shares.
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
The global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.
Protagonist Therapeutics Announces $300M Buyback Plan
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.